Your latest cannabis business info from Europe

Your latest cannabis business info from Europe


NHS joins forces with Ananda for MRX1 endometriosis trial

NHS Scotland joins forces with Ananda for MRX1 endometriosis trial

Ananda Developments has announced a new collaboration with NHS, marking a notable advance in endometriosis pain management with their new MRX1 cannabinoid oil.

Ananda is undoubtedly a pioneering company, with a mission of redefining cannabinoid-based medications for complex inflammatory pain diseases. An innovative endometriosis randomised controlled trial (“RCT”) utilising Ananda’s innovative MRX1 cannabidiol oil is expected to be supported by the Chief Scientist Office (“CSO”), a crucial division of the Scottish Government Health Directorate dedicated to funding NHS Scotland research. With the help of this sizable non-dilutive funding of £300,000, the experiment will be guided by Ananda’s patent-pending MRX1 formulation and a meticulously developed placebo.

Ananda: shaping the future of endometriosis pain management

The endometriosis RCT, which is being led by Professor Andrew W Horne, Professor of Gynecology and Reproductive Sciences at the same institution, and Dr. Lucy H R Whitaker, NES CSO Clinical Lecturer in Obstetrics and Gynecology at The University of Edinburgh, holds great promise.

The focus of the study will be on 100 people in fact. The NHS trial will include Ananda patent-pending MRX1 cannabidiol oil and its placebo equivalent. The CEO of Ananda, Melissa Sturgess, emphasised the importance of the project. She said:

“Our objective is to have MRX1 included by the NHS as an efficacious and cost-effective treatment for pain associated with endometriosis.”

This collaboration highlights the growing importance of endometriosis as a problem for public health. It also shows the growing interest in cannabidiol’s ability to treat complicated chronic inflammatory pain diseases. There is a projected annual value of £5 billion in the UK alone. The expanding chronic pain market may change as a result of this partnership.

Exploring cannabinoids potential

The TCS/22/28 – ENDOCAN-1 study aims to determine the effectiveness of an oral tincture containing cannabinoids in reducing pain brought on by endometriosis. The research aims to realise the potential of cannabinoids, derived from cannabis. It aims to verify possibility of controlling the severe discomfort associated with endometriosis. This disorder affects around 190 million women worldwide.

100 women suffering from endometriosis pelvic pain will take part in the pilot research. It will take place across two Scottish hospitals. During a twelve-week period, women will receive either Ananda’s cannabidiol tincture or a placebo. A carefully thought-out double-blind framework maintains objectivity by keeping participants’ and medical teams’ knowledge of the treatment allocations a secret.

Undeniably, ENDOCAN-1 is a first step toward a thorough UK-wide trial through questionnaires and participant interviews. This broader project attempts to determine whether cannabis hold the answer to reducing pain caused by endometriosis. All while providing patients with the best possible care. Finally, through journals, conferences, and social media platforms, the trial’s findings will be available to the public and the medical community. Results may create a new era of pain management.

In brief, the landscape of pain management is changing as Ananda forges this ground-breaking partnership with NHS Scotland, with cannabinoid-based innovations paving the way for a better future for those navigating the complexities of inflammatory pain diseases.


Medical cannabis in Portugal: filling the gap of Clever Leaves

CBD at treating skin ulcers


Sustainability and growth in the hemp&cannabis industry: Synbiotic